Mayne Pharma Group Ltd (MYX) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Mayne Pharma Group Ltd stock A$4.13, price A$3.27, upside +26.3%, quality 43 out of 100. Rating: undervalued. Calculated from audited financials with 19 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range A$2.13 – A$7.65 · fair‑value band A$2.89 – A$5.75 · the A$3.27 price screens below the A$4.13 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.
Follow Mayne Pharma Group in your weekly email
Every Wednesday you see whether Mayne Pharma Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
Show moreShow less
It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers.
It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010.
Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Stock analysis
Mayne Pharma Group Ltd (MYX) currently trades at A$3.27, while our model-based Fair Value estimate is A$4.13, implying the stock looks roughly 21% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of A$6.05 per share, and 15 of the 19 models we run sit above the A$3.27 price.
Bear case: the Economic Profit group reads lowest at A$3.37, and 4 of the 19 models stay below the price. Data coverage for this calculation is medium.
Scenario range: A$2.89 (bear) to A$5.75 (bull), the price of A$3.27 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Mayne Pharma Group Ltd reported revenue of A$384M in FY2026 versus A$157M in FY2022, a compound +25.0%/yr. Reported net income was A$24.5M in FY2026.
Key figures
Market cap A$309M (≈ $213M) Micro · P/S ratio 0.56 · EPS (TTM) A$0.3100 · Net margin 6.4% · Return on equity 8.2% · Return on assets (EBIT) −8.5% (5-year average) · Operating margin −2.9% · Revenue (TTM) A$384M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 54% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at 26%, MYX screens richer than that median.
Fair Value models
BearA$2.89Fair Value A$4.13BullA$5.75
Price A$3.27 · Upside +26.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 4 months old). Earnings retained since then (A$0.1121 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCFA$2.56A$3.78A$5.5680
Growth DCFA$2.52A$3.55A$4.9479
Owner EarningsA$12.33A$19.66A$30.3975
All 19 models by family
DCF Models
FCF DCFA$2.56A$3.78A$5.5680
Owner EarningsA$12.33A$19.66A$30.3975
5Y Revenue ExitA$2.22A$3.26A$4.6573
5Y EBITDA ExitA$3.44A$5.82A$8.8474
5Y P/E ExitA$4.07A$7.13A$10.7069
10Y Revenue ExitA$2.30A$3.25A$4.6767
10Y EBITDA ExitA$3.03A$4.86A$7.6967
10Y P/E ExitA$3.39A$5.68A$9.0462
Earnings-Based
Graham-DoddA$2.03A$9.95A$13.7264
Lynch FVA$2.67A$3.82A$4.9761
PEG = 1.0A$2.67A$3.82A$4.9757
Multiples
P/E MultipleA$4.93A$6.57A$8.2263
P/S MultipleA$3.81A$5.08A$6.3558
EV/EBITDAA$4.25A$5.50A$6.7667
EV/RevenueA$1.89A$2.49A$3.0954
Growth DCF
Growth DCFA$2.52A$3.55A$4.9479
Rev-Margin DCFA$2.22A$3.25A$4.6073
Economic Profit
Residual IncomeA$3.40A$3.37A$3.5571
Growth Earnings
Growth-Adj P/EA$4.24A$6.05A$7.8767
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−6.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.9%
Start year 2021 (pandemic). Over 10 years: +3.7% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−43.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−43.2%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−3% → −9%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about +16.0% a year for the price and −1.1% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks
Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside+26.3% · Above median
Profitability
Return on equity (12 months)8.2% · Above median
Return on assets2.7% · Above median
Net margin (12 months)6.4% · Top 25%
Operating margin (12 months)−2.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−12.0% · Bottom 25%
Balance sheet
Debt / equity0.08× · Above median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/B0.79× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Mayne Pharma Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/MYX
Frequently asked questions
Is Mayne Pharma Group Ltd (MYX) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of A$4.13 versus a price of A$3.27, about +26% upside (undervalued).
What is the fair value of MYX?
Our model-based fair value for Mayne Pharma Group Ltd is A$4.13 (as of Nov 6, 2026), built from audited fundamentals. The current price: A$3.27.
What is the quality score of MYX?
Mayne Pharma Group Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mayne Pharma Group Ltd (MYX)?
Our model-based price target is the fair value of A$4.13 (as of Nov 6, 2026) from 19 valuation models. Cautious scenario A$2.89, optimistic scenario A$5.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Mayne Pharma Group Ltd stock forecast for 2026?
Our models put fair value at A$4.13, about +26% upside versus a price of A$3.27 (undervalued). Cautious scenario A$2.89, optimistic scenario A$5.75. The calculation is refreshed regularly with new filings.
What is the revenue of Mayne Pharma Group Ltd (MYX)?
Mayne Pharma Group Ltd reported trailing-twelve-month revenue of about A$384M (latest available figure, as of Nov 6, 2026).
What growth is priced into Mayne Pharma Group Ltd (MYX)?
For today's price to be fair in a discounted-cash-flow model, Mayne Pharma Group Ltd would have to grow free cash flow by +19.5 % per year for five years (discount rate 12.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.9 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of MYX use?
Our models discount Mayne Pharma Group Ltd at 12.6 %: a base by market capitalisation (micro), damped by beta 1.03, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Mayne Pharma Group Ltd that is +19.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.6 %) and the same formula as our fair value.
How much growth has Mayne Pharma Group Ltd (MYX) delivered so far?
Over the past 5 years revenue at Mayne Pharma Group Ltd grew -0.9 % a year. The price currently implies free-cash-flow growth of +19.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Mayne Pharma Group Ltd (MYX) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Mayne Pharma Group Ltd (+19.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Mayne Pharma Group Ltd (MYX)?
The free-cash-flow yield on the price is 4.10 %: that much free cash flow Mayne Pharma Group Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Mayne Pharma Group Ltd (MYX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mayne Pharma Group Ltd it is A$4.13 per share (as of Nov 6, 2026), against a price of A$3.27. It is the blended result of 19 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Mayne Pharma Group Ltd stock overvalued or undervalued in 2026?
As of Nov 6, 2026, MYX trades below its calculated fair value: price A$3.27, fair value A$4.13, a gap of about +26% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MYX?
No. The price is what the market pays today (A$3.27); the fair value is what the company's own numbers justify (A$4.13). For Mayne Pharma Group Ltd the two are A$0.8610 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mayne Pharma Group Ltd worth?
The market values Mayne Pharma Group Ltd at about A$309M (market capitalisation, as of Nov 6, 2026). Per share that is A$3.27; our models calculate a fair value of A$4.13 per share.
What do the bullish and bearish scenarios say about MYX?
Our models span a range for Mayne Pharma Group Ltd: cautious scenario A$2.89, base A$4.13, optimistic A$5.75 per share (as of Nov 6, 2026, price A$3.27). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MYX?
The PEG ratio of Mayne Pharma Group Ltd is 2.52 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Mayne Pharma Group Ltd (MYX)?
Balance-sheet figures for Mayne Pharma Group Ltd (as of Nov 6, 2026): return on equity 8.2%, debt of 0.08 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is MYX from its 52-week high?
Mayne Pharma Group Ltd trades at A$3.27, about 44% below its 52-week high of A$5.79 and 54% above the low of A$2.13 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$4.13 is for.
Which stocks are comparable to Mayne Pharma Group Ltd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mayne Pharma Group Ltd stock attractive at the current price?
The data as of Nov 6, 2026: price A$3.27, calculated fair value A$4.13 (+26%), Quality Score 43/100, from 19 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MYX calculated?
We run Mayne Pharma Group Ltd through 19 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of A$4.13 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Mayne Pharma Group Ltd currently trades 21% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mayne Pharma Group Ltd (MYX)?
The closing price on Nov 9, 2026 was A$3.27. Our model-based fair value is A$4.13, about +26% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mayne Pharma Group Ltd right now?
A fairly wide model range (A$2.89 to A$5.75) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Mayne Pharma Group Ltd
How large is the market capitalisation of Mayne Pharma Group Ltd (MYX)?
The market capitalisation of Mayne Pharma Group Ltd is A$309M (≈ $213M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mayne Pharma Group Ltd (MYX)?
The price-to-sales ratio of Mayne Pharma Group Ltd is 0.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mayne Pharma Group Ltd (MYX)?
Earnings per share at Mayne Pharma Group Ltd are A$0.3100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Mayne Pharma Group Ltd (MYX)?
The net margin of Mayne Pharma Group Ltd is 6.4% (last twelve months), excl. one-off gain FY2026 −19.2%. How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mayne Pharma Group Ltd (MYX)?
The return on equity (ROE) of Mayne Pharma Group Ltd is 8.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mayne Pharma Group Ltd (MYX)?
On an EBIT basis the return on assets of Mayne Pharma Group Ltd is −8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mayne Pharma Group Ltd (MYX)?
The operating margin of Mayne Pharma Group Ltd is −2.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mayne Pharma Group Ltd (MYX)?
Revenue at Mayne Pharma Group Ltd is growing −12.0% versus a year earlier (3y avg +27.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Mayne Pharma Group Ltd (MYX) hold?
Mayne Pharma Group Ltd holds more cash than debt, A$39.1M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Mayne Pharma Group Ltd in the live analysis
One click puts Mayne Pharma Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026